Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lifecore Biomedical's Enterprise Value is €264.52 Mil.
Lifecore Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €6.00 Mil. Therefore, Lifecore Biomedical's EV-to-FCF for today is 44.07.
The historical rank and industry rank for Lifecore Biomedical's EV-to-FCF or its related term are showing as below:
FRA:LDE'
s EV-to-FCF Range Over the Past 10 Years
Min: -458.98 Med: -15.89 Max: 1916.83
Current: 43.93
During the past 13 years, the highest EV-to-FCF of Lifecore Biomedical was 1916.83. The lowest was -458.98. And the median was -15.89.
FRA:LDE's EV-to-FCF is ranked worse than 70.74% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs FRA:LDE: 43.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lifecore Biomedical's PE Ratio (TTM) for today is calculated as:
Lifecore Biomedical's share price for today is €3.98.
Lifecore Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.672.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lifecore Biomedical EV-to-FCF Related Terms
Lifecore Biomedical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's EV-to-FCF falls into.
Lifecore Biomedical's current Enterprise Value is €264.52 Mil.
Lifecore Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (FRA:LDE) has a EV-to-FCF of 44.07 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lifecore Biomedical and its competitors. According to the industry distribution chart, Lifecore Biomedical ranks #399 out of 564 companies in the Drug Manufacturers industry, placing it in the top 70.7%.
Is Lifecore Biomedical's EV-to-FCF too high?
Lifecore Biomedical's current EV-to-FCF is 44.07. The Drug Manufacturers industry median EV-to-FCF is 20.90. Lifecore Biomedical's value of 44.07 is 110.9% above this industry median. Based on the distribution chart, Lifecore Biomedical ranks #399 out of 564 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lifecore Biomedical has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's EV-to-FCF compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #399 out of 564 companies for EV-to-FCF. This places Lifecore Biomedical in the lower half of its industry. The industry median EV-to-FCF is 20.90. Lifecore Biomedical's value of 44.07 is 110.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current EV-to-FCF of 44.07 is 110.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current EV-to-FCF is 44.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (FRA:LDE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.64, compared to a current price of €3.98 — trading 29.4% below its estimated fair value. The current EV-to-FCF is 44.07 and 110.9% above the Drug Manufacturers industry median of 20.90. Lifecore Biomedical's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lifecore Biomedical (FRA:LDE), the current EV-to-FCF is 44.07 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (FRA:LDE) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of €3.98 is trading 29.4% below its estimated GF Value™ of €5.64.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for FRA:LDE:
EV-to-FCF: 44.07
GF Value™: €5.64 vs. price of €3.98 (29.4% below fair value)
Industry Position: 110.9% above the Drug Manufacturers median (#399 of 564)
No single metric tells the full story. See the FRA:LDE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
58GF Score
Get the complete analysis for FRA:LDE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDE has been successfully added to your 
